InMed Provides Update on Management Changes

InMed Pharmaceuticals Inc. announces that Sarah Li has been promoted to Vice President of Accounting and Controller at InMed. Ms. Brenda Edwards will be transitioning out of her position as interim Chief Financial Officer at the Company effective November 20, 2022. Ms. Edwards joined the Company in an interim contract role to assist the Company with financial reporting matters following the retirement of the Company’s former Chief Financial Officer in March 2022...READ MORE

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Corp, a clinical-stage company and leader in cell therapeutics, announced that the first two patients in the second cohort of its active U.S. Phase 1/2 type 1 diabetes clinical trial have been implanted with its 10- channel Cell Pouch, which provides >50% more capacity relative to the Cell Pouches used for the first cohort. The transition to this new 10-channel Cell Pouch under the revised protocol enables optimized dosing and shorter efficacy evaluation periods to ultimately decrease time to key efficacy endpoints...READ MORE

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (“NSERC”) Alliance Grant Funding

InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces the launch of its neurodegenerative disease program (INM-900 series), which will be investigating the effects of cannabinoid analogs in diseases such as Alzheimer’s, Huntington’s and Parkinson’s...READ MORE

Thrive Health Ranked #1 in Deloitte’s 2022 Technology Fast 50 Companies-to-Watch Award

Thrive Health has been ranked #1 in Deloitte’s 2022 Technology Fast 50 Companies to Watch list. Celebrating its 25th anniversary, the award recognizes emerging companies based on their revenue growth percentage. The category for which Thrive Health is recognized, “Companies-to-Watch,” specifically celebrates fifteen start-ups that demonstrate exceptional potential for continued growth and leadership in their industry...READ MORE

[Ad Hoc Announcement Pursuant to Art. 53 LR] Roche Provides Update on Phase III GRADUATE Programme Evaluating Gantenerumab in Early Alzheimer’s Disease

Roche announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia, collectively called early Alzheimer’s disease. The studies did not meet their primary endpoint of slowing clinical decline. Gantenerumab was well tolerated, including the subcutaneous administration...READ MORE

AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022

AbCellera announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022. AbCellera’s poster presentation describes the expansion, further characterization, and validation of a diverse panel of CD3-binding antibodies that can be used to develop T-cell engagers for cancer treatments...READ MORE

Implementation of the Patented Medicine Prices Review Board’s Proposed Guidelines Will Harm Canadian Patients

Innovative Medicines Canada is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) to suspend its current Guidelines consultation process. If the PMPRB’s revised draft Guidelines are implemented without substantial changes as planned for the beginning of 2023, Canadian patients will be deprived of potentially life-saving new medicines. The uncertainty caused by the proposed Guidelines will result in fewer clinical trials, delayed drug launches, and decreased investments in the life sciences sector...READ MORE

Evonik Wins Pharma Award for Polymer-Based Technology for mRNA Delivery

Evonik Health Care has won the prestigious CPHI Excellence in Pharma Award in the category “Packaging and Drug Delivery”. The winning innovation is a new polymer-based drug delivery system for mRNA and other nucleic acids – developed together with researchers at Stanford University. This award is the latest highlight for Evonik’s mRNA and nucleic acid delivery business. Earlier this year, the company announced a joint investment with the U.S. Government of US$220 million to build the world’s largest lipid production plants at its site in Tippecanoe, Indiana...READ MORE

The Canadian Inflammatory Bowel Disease Research Consortium Awards First $1M Pioneer Grant from Takeda Canada

The Canadian Inflammatory Bowel Disease Research Consortium (CIRC) awards the inaugural $1 million PIONEER Grant from Takeda Canada Inc. (Takeda), in support of high-quality, impactful Canadian clinical research to improve patient outcomes and quality of life for people living with inflammatory bowel disease (IBD)...READ MORE

INOVAIT Pilot Fund 2022 Call for Applications

INOVAIT currently has an open call for applications for its $125,000 Pilot Fund. The program offers funding to support collaborative commercialization-focused research and development projects involving the integration of artificial intelligence into image-guided therapy technologies…READ MORE

Director, Medicinal Chemistry

The Research and Innovation Manager, Data Science is a collaborative member of the Research and Innovation team and works seamlessly across the organization. Reporting to the Data Science Lead you will work with the Research and Innovation leadership and the other members of the Data Science team to implement Genome BC's Data Science Strategy. You will engage external partners to catalyze partnerships across the innovation and research ecosystem in BC, consistent with the organization’s mandate. You are one of the main points of contact at Genome BC for funded project teams and you are responsible for monitoring projects to assess progress and maximize outcomes.

LEARN MORE

Senior Manager Biostatistics

The Senior Manager, Biostatistics is responsible for providing in-house statistical expertise and support for Eupraxia’s clinical development programs, as well as for related investigator-initiated studies. Providing expert statistical advice in the design and review of analysis and reporting plans of clinical trials, integrated summaries and other regulatory documents, investigator-initiated study proposals and independent Data Safety Monitoring Board data requirements, writing statistical study design sections of clinical protocols, statistical analysis plans, mock Table and Figure Listings, study committee data requirements, study reports and/or other reports, regulatory submission materials such as integrated summaries.

LEARN MORE

Associate Director/Director, Pharmacovigilance and Drug Safety (Safety Scientist)

This individual will conduct case processing activities as needed and aggregate data review for Xenon’s clinical drugs to support product safety and compliance with global drug safety regulations and departmental procedures and provide vendor oversight to CROs for HCP steps of case processing activities. The lead will also contribute to the triage, case review, narrative writing, analysis of similar events of the Individual Case Safety Reports (ICSR) and Periodic Reports for Xenon’s investigational products. This individual also provides pharmacovigilance oversight for Xenon’s products, including safety scientific input for safety surveillance, signal detection, benefit-risk assessment, and risk management activities.

LEARN MORE

ezPT Technologies Ltd is developing tech that reduces burnout of physical therapists working in Outpatient Orthopedic clinics and improves outcome measures of patients undergoing treatment for Musculoskeletal conditions.

Visit Website

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology-focused therapies to address areas of high unmet medical need, with a focus on epilepsy.

Visit Website